


Listing of Claims:


Please note the claims remain as follows, noting also that this listing of claims technically replaces all prior versions, and prior listings of claims in the application:

1. (Currently Amended) A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

-G<sub>1</sub> is a radical (II)




wherein -R' is an electron pair or a (C<sub>1</sub>-C<sub>3</sub>)-alkyl radical; with the condition that


(i) when -R' is an electron pair, a is a N=C double bond and the fused ring



is the biradical




thus radical (II) is (IIa'), and




(IIa')

(ii) when  $-R'$  is a  $(C_1-C_3)$ -alkyl radical, a is a N-C single bond and the fused ring

is the triradical



thus radical (II) is (IIa'');




(IIa'')

wherein  $-R_1$  to  $-R_{12}$  represent radicals, same or different, selected from the group consisting of H,  $(C_1-C_4)$ -alkyl,  $(C_1-C_4)$ -alkoxy,  $(C_1-C_4)$ -alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;

and wherein  $-B-$  is a biradical selected from the group consisting of  $-CONH-$ ,

~~-NR<sub>13</sub>- , -O- , -(CH<sub>2</sub>)<sub>n</sub>NH- , and -(CH<sub>2</sub>)<sub>n</sub>O- , and -CO[NHCHR"CO]<sub>m</sub>O- ; wherein -R<sub>13</sub> is selected from the group consisting of H, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy and (C<sub>1</sub>-C<sub>4</sub>)-alkylamino; -R" are side chains radicals, same or different, corresponding to natural aminoacids; and n is an integer from 1 to 3 and m is an integer from 1 to 3;~~


~~-L- is a single covalent bond or a covalent linking biradical selected from the following ones;~~



wherein -R''' and -R'''' are radicals, same or different, selected from the group consisting of H and (C<sub>1</sub>-C<sub>3</sub>)-alkyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and

-G<sub>2</sub> is a radical selected from a radical of formula (II), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.

2. (Previously Presented) The compound according to claim 1, wherein (II) is the radical (IIa').




3. (Original) The compound according to claim 2, wherein -B- is selected from the group consisting of -CONH- and -NR<sub>13</sub>- .

4. (Withdrawn from Consideration) The compound according to claim 2, wherein -B- is -CO[NHCHR"CO]<sub>m</sub>O- .

5. (Withdrawn from Consideration) The compound according to claim 4, wherein  $m = 2$ , the leftward  $-R''$  is a glycine side chain, and the rightward  $-R''$  is an arginine side chain.

6. (Withdrawn from Consideration) The compound according to claim 2, wherein  $-L-$  is a single covalent bond.


7. (Previously Presented) The compound according to claim 2, wherein  $-L-$  is a covalent linking biradical selected from the following ones.



8. (Previously Presented) The compound according to claim 7, wherein  $-L-$  is the biradical  $-(CH_2)_rNR'''(CH_2)_s-$ ,  $-R'''$  is methyl, and both  $r$  and  $s$  are 3.

9. (Previously Presented) The compound according to claim 7, wherein  $-L-$  is the covalent linking biradical  $-(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t-$ , both  $-R'''$  and  $-R''''$  are methyl; both  $r$  and  $t$  are 2, and  $s$  is 2 or 3.

10. (Previously Presented) The compound according to claim 1, wherein (II) is the radical (IIa'').



11. (Previously Presented) The compound according to claim 10, wherein  $-B-$  is selected from the group consisting of  $-CONH-$  and  $-NR_{13}-$ .

12. (Withdrawn from Consideration) The compound according to claim 10, wherein  $-B-$  is  $-CO[NHCHR''CO]_mO-$ .

13. (Withdrawn from Consideration) The compound according to claim 12, wherein  $m = 2$ , the leftward-R" is a glycine side chain, and the rightward -R" is the arginine side chain.

14. (Previously Presented) The compound according to claim 10, wherein -R' is methyl.

15. (Withdrawn from Consideration) The compound according to claim 14, wherein -L- is a single covalent bond.

16. (Previously Presented) The compound according to claim 14, wherein -L- is a biradical selected from the following ones.



17. (Previously Presented) The compound according to claim 16, wherein -L- is the biradical  $-(CH_2)_rNR'''(CH_2)_s-$ , R''' is methyl, and both r and s are 3.

18. (Previously Presented) The compound according to claim 16, wherein -L- is the biradical  $-(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t-$ , both -R''' and -R'''' are methyl; both r and t are 2, and s is an integer from 2 to 3.

19. (Previously Presented) The compound according to claim 1, which is selected from the group consisting of:

N-[3-[[3-[(9-acridinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (1a);

N,N'-(4-methyl-4-azaheptamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (1b);

N-[3-[3-[[2-(1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinoliny]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (1c);

N-[3-[[3-[(2-phenyl-4-quinolinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (1d);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ie);

N-[(9-acridinecarbonyl)-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (If);

N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide (Ig);

N-[(9-acridinecarbonyl)-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ih);

N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ii);

N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ij);

N,N'-(4-methyl-4-azaheptamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Im);

N,N'-(4-methyl-4-azaheptamethylen)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iq);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iy);


N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iz);

(3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide (Iaa);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iab); and


N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iac).

20. (Currently Amended) A method for the treatment of cancer which comprises administering to a subject a therapeutically effective amount of a compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

-G<sub>1</sub> is a radical (II)




wherein -R' is an electron pair or a (C<sub>1</sub>-C<sub>3</sub>)-alkyl radical; with the condition that


(i) when -R' is an electron pair, a is a N=C double bond and the fused ring



is the biradical




thus radical (II) is (IIa'), and




(IIa')

(ii) when -R' is a (C<sub>1</sub>-C<sub>3</sub>)-alkyl radical, a is a N-C single bond and the fused ring

is the triradical



thus radical (II) is (IIa'');



(IIa'')



wherein  $-R_1$  to  $-R_{12}$  represent radicals, same or different, selected from the group consisting of H, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, (C<sub>1</sub>-C<sub>4</sub>)-alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;

and wherein  $-B-$  is a biradical selected from the group consisting of  $-\text{CONH}-$ ,  $-\text{NR}_{13}-$ ,  $-\text{O}-$ ,  $-(\text{CH}_2)_n\text{NH}-$ , and  $-(\text{CH}_2)_n\text{O}-$ , ~~and  $-\text{CO}[\text{NHCHR}''\text{CO}]_m\text{O}-$~~ ; wherein  $-R_{13}$  is selected from the group consisting of H, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy and (C<sub>1</sub>-C<sub>4</sub>)-alkylamino;  ~~$-R''$  are side chains radicals, same or different, corresponding to natural aminoacids; and  $n$  is an integer from 1 to 3 and  $m$  is an integer from 1 to 3;~~

~~$-L-$  is a single covalent bond or~~ a covalent linking biradical selected from the following ones;




wherein  $-R'''$  and  $-R''''$  are radicals, same or different, selected from the group consisting of H and (C<sub>1</sub>-C<sub>3</sub>)-alkyl;  $r$  is an integer from 1 to 3;  $s$  is an integer from 1 to 3;  $t$  is an integer from 1 to 3; and

$-G_2$  is a radical selected from a radical of formula (II), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.

21. (Previously Presented): A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in claim 1, together with appropriate amounts of pharmaceutical excipients or carriers.


22. (Previously Presented): A method of manufacturing a composition of matter comprising formula (I) and one of the following processes:

Process I:




when biradical -B- in -G<sub>1</sub> is -CONH- and -G<sub>2</sub> is not an N-radical of 1,8-naphthalimide; and wherein GP represents an amino protective group and wherein formula (IV) is a monoprotected bis-amine; or

Process II:



when biradical -B- in -G<sub>1</sub> is -CONH- and -G<sub>2</sub> is 1,8-naphthalimide; and  
 wherein GP represents an amino protective group and wherein formula (IV) is a  
 monoprotected bis-amine; or

Process III:



when biradical -B- is a biradical selected from a group of: -NR<sub>13</sub>-, -O-, -(CH<sub>2</sub>)<sub>n</sub>NH, and -(CH<sub>2</sub>)<sub>n</sub>O-; and

wherein GP represents an amino protective group.

23. (New) A method for the treatment of cancer as claimed in Claim 20, wherein the cancer is one or more of lung cancer and leukemia.